PerioPredict® Named “Best New Hygienist Product”
WALTHAM, MA – October 13, 2014 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today it received the 2014 DrBicuspid Dental Excellence Award for PerioPredict®, the Company’s commercially available genetic risk test for periodontal disease. PerioPredict® was recognized as the “Best New Hygienist Product” and Kenneth S. Kornman, DDS, PhD, Chief Executive Officer, was presented with the award at this week’s 2014 American Dental Association (ADA) Annual Meeting.
“PerioPredict® is an innovative, easy-to-use tool that enables dental professionals to identify individuals with a higher risk of progressing to severe periodontal disease, and therefore better align preventive care to an individual patient’s needs,” said Dr. Kornman. “We believe that PerioPredict® offers the potential to improve outcomes for dental patients and ultimately reduce long-term oral healthcare expenses. This award is a powerful endorsement of our product and it is very rewarding to see it be received so positively by our professional community.”
The Dental Excellence Awards are based on votes cast by more than 50,000 dental professionals and recognize the very best people, products and services that are helping to improve dental health. The votes are cast by members of the DrBicuspid.com professional community and DrBicuspid.com readers, and honor the best of what dentistry has to offer.
The PerioPredict® genetic test is quick, easy and painless and is performed by dentists during a routine exam or cleaning. PerioPredict® measures variations in genes for Interleukin-1 (IL-1), a key mediator of inflammation, and identifies individuals who are at increased risk for moderate to severe periodontal disease. The PerioPredict® test results provide essential information to the dental professional for assessing prevention and treatment options for their patients. PerioPredict® is run solely in the Interleukin Genetics CLIA-certified lab in Waltham, MA. For more information, visit www.PerioPredict.com.
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ flagship products include its proprietary PerioPredict® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit 188.8.131.52.
Certain statements contained herein are “forward-looking” statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company’s annual report on Form 10-K for the year ended December 31, 2013 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.
|David Pitts||Susan Kim|
|Argot Partners||Argot Partners|